MAXCYTE INC. - COMMON STOCK

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

12 июл 2022 08:00:01 Источник Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 май 2022 16:30:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports First Quarter Financial Results

09 май 2022 16:05:03 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

03 май 2022 16:05:01 Источник Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

20 апр 2022 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 апр 2022 09:00:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

12 апр 2022 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year Financial Results

22 мар 2022 16:05:01 Источник Nasdaq GlobeNewswire

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

09 мар 2022 16:15:00 Источник Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

24 фев 2022 08:00:01 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

14 фев 2022 08:00:01 Источник Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 фев 2022 17:00:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

01 фев 2022 02:00:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

24 янв 2022 02:30:00 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

12 ноя 2021 08:00:01 Источник Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter Financial Results

10 ноя 2021 16:00:00 Источник Nasdaq GlobeNewswire

MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board

03 ноя 2021 09:00:02 Источник Nasdaq GlobeNewswire

Result of AGM

29 окт 2021 12:40:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

28 окт 2021 10:00:00 Источник Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

25 окт 2021 16:30:00 Источник Nasdaq GlobeNewswire